Following his presentation at ACR 2020 we spoke with Ronald van Vollenhoven (Amsterdam University Medical Centers, Amsterdam, the Netherlands) regarding upadacitinib monotherapy in methotrexate-naïve patients with rheumatoid arthritis. (Clinical Trial Identifier: NCT02706873). The abstract ‘Upadacitinib Monotherapy in Methotrexate-naïve Patients with Rheumatoid Arthritis: Results at 72 Weeks’ (ABSTRACT NUMBER: 0207) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
- What is the rationale for the use of JAK inhibitors in the treatment of rheumatoid arthritis (RA)? (0:25)
- How does upadacitinib fit into the current treatment paradigm for RA? (1:52)
- Could you give us an overview of the SELECT-EARLY study and its findings? (3:19)
- What have the latest data taught us about the long term efficacy and safety of upadacitinib? (4:27)
- What are the remaining gaps in our knowledge regarding the optimal use of upadacitinib in RA, and what further studies are planned? (5:35)
Disclosures: Research Support (institutional grants): BMS, GSK, Lilly, UCB. Support for Educational programs (institutional grants): Pfizer, Roche. Consultancy, for which institutional and/or personal honoraria were received: AbbVie, AstraZeneca, Biogen, Biotest, Celgene, Galapagos, Gilead, Janssen, Pfizer, Sanofi, Servier, UCB. Speaker, for which institutional and/or personal honoraria were received: AbbVie, Galapagos, Janssen, Pfizer, UCB.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual)
Share this Video
Related Videos In Rheumatoid Arthritis
Anthony Sebba, ACR 2020 – Pain in Patients with Rheumatoid Arthritis (Part 1)
We were delighted to speak to Anthony Sebba (Arthritis Associates, FL, USA) to discuss whether pain and inflammation are independent of each other in patients with rheumatoid arthritis. The abstract ‘Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints in […]
Peter C Taylor, ACR 2020 – Therapy Reduction in RA Patients in Remission: The SEAM-RA Trial (Part 1)
Following ACR Convergence 2020 we speak with Peter C Taylor (University of Oxford, Oxford, UK) about his highlights from the meeting. Part 1 in the series covers the SEAM-RA study designed to investigate the effect of therapy reduction in RA patients with persistent submission receiving a combination of methotrexate and etanercept. The abstract entitled ‘Maintenance […]
Anthony Sebba, ACR 2020 – Pain in Patients with Rheumatoid Arthritis (Part 3)
After his presentation at ACR 2020, we spoke with Anthony Sebba (Arthritis Associates, FL, USA) about the importance of studying pain as a patient reported outcome in rheumatoid arthritis and what further studies are needed. The abstract ‘Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!